ASP 0819
Alternative Names: ASP0819Latest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Analgesics
- Mechanism of Action Calcium-activated potassium channel openers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibromyalgia
Most Recent Events
- 27 Oct 2020 No development reported - Phase-II for Fibromyalgia in USA (PO)
- 12 Sep 2018 Pharmacodynamics data from a preclinical trial in Pain presented at the 17th World Congress on Pain (WCP-2018)
- 12 Sep 2018 Pharmacokinetics and adverse events data from a first-in-human phase I trial in Healthy volunteers presented at the 17th World Congress on Pain (WCP-2018)